Гематология / лейкозы / лимфомы

Debate: The Future Role of BCMA Bispecific Antibodies in Later-Line Relapsed/Refractory Multiple Myeloma

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia - University of Cincinnati

Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia University of Cincinnati

Finding Support Through the Relapsed/Refractory Multiple Myeloma Journey

Multidisciplinary Support in Relapsed/Refractory Multiple Myeloma

<![CDATA[Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma]]>

<![CDATA[CELMoD Mechanism and Differentiation From IMiDs in Multiple Myeloma]]>

<![CDATA[How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma?]]>

<![CDATA[Introduction and Overview of CELMoDs in Multiple Myeloma]]>

<![CDATA[Matthew Matasar, MD: Lymphoma Specialist Navigating the Immunotherapy Era]]>

<![CDATA[Soquelitinib Monotherapy Yields Durable Responses in Peripheral T-Cell Lymphoma ]]>

<![CDATA[Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?]]>

Three-drug treatment regimen shows promise for difficult-to-treat brain lymphoma

A collaborative clinical study led by National Taiwan University Hospital (NTUH) and Taiwan Clinical Oncology Group, National Health Research Institutes (TCOG, NHRI) has yielded promising results for a new therapeutic regimen to treat primary central nervous system lymphoma (PCNSL), a rare and aggressive cancer that…

<![CDATA[CELMoD Wins “Landmark Approval” in Relapsed/Refractory Multiple Myeloma]]>

<![CDATA[Debate: Class Effect Versus Meaningful Differences Among BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma]]>